RT @GuyattGH: Important RCT depression treatment shows limitations of cluster randomization. Clinicians in low dose arm hesitated to enrol…
RT @GuyattGH: Important RCT depression treatment shows limitations of cluster randomization. Clinicians in low dose arm hesitated to enrol…
RT @GuyattGH: Important RCT depression treatment shows limitations of cluster randomization. Clinicians in low dose arm hesitated to enrol…
RT @GuyattGH: Important RCT depression treatment shows limitations of cluster randomization. Clinicians in low dose arm hesitated to enrol…
Important RCT depression treatment shows limitations of cluster randomization. Clinicians in low dose arm hesitated to enrol sicker patients; high dose no problem; result prognostic imbalance. Sophisticated statistical analysis saved the day, but not ideal
『(#京都大学 大学院 教授 が #ミルタザピン の)9週目の一時的な小さい有益性を強調した。「25週目では #有効性(#PHQ9 #BDI2 #寛解)#耐用性(中止までの期間)#有害転帰 の何れも #統計学的有意 な群間差は示されなかった。」』 上級講師 https://t.co/HfhPT9W3RV https://t.co/oxNqYGXshA
@rojasfec True. And our megatrial (970 vs 1041) showed that 50 mg of sertraline was just as good or bad as 100 mg of sertraline. https://t.co/Yd6fAX4F6X
@AAMortazavi @eturnermd1 In the same vein: "we found no advantage of titrating sertraline to 100 mg vs 50 mg" https://t.co/xS5iswygHA
RT @Toshi_FRKW: And lastly, may I suggest some alternative ways when we face such limitations in practice? Switch or combine, and as early…
RT @Toshi_FRKW: And lastly, may I suggest some alternative ways when we face such limitations in practice? Switch or combine, and as early…
RT @Toshi_FRKW: And lastly, may I suggest some alternative ways when we face such limitations in practice? Switch or combine, and as early…
RT @Toshi_FRKW: And lastly, may I suggest some alternative ways when we face such limitations in practice? Switch or combine, and as early…
RT @Toshi_FRKW: And lastly, may I suggest some alternative ways when we face such limitations in practice? Switch or combine, and as early…
And lastly, may I suggest some alternative ways when we face such limitations in practice? Switch or combine, and as early as at 3 weeks (https://t.co/Yd6fAX4F6X). But NEVER escalate, I mean almost never because the reality always has exceptions.
RT @manabunoda: ご視聴いただいた皆様、ありがとうございました! 頑張って今からブログ書きます! https://t.co/WqESdUXFwi
RT @manabunoda: ご視聴いただいた皆様、ありがとうございました! 頑張って今からブログ書きます! https://t.co/WqESdUXFwi
ご視聴いただいた皆様、ありがとうございました! 頑張って今からブログ書きます!
RT @manabunoda: 今日の夜22時くらいからエビテンをします! 毎度毎度の音声トラブル…今回はうまくいくはず… 今回はこの3つを https://t.co/ZuHnKsXUKt https://t.co/Bibn4X4HdE https://t.co/1Crjwb…
RT @manabunoda: 今日の夜22時くらいからエビテンをします! 毎度毎度の音声トラブル…今回はうまくいくはず… 今回はこの3つを https://t.co/ZuHnKsXUKt https://t.co/Bibn4X4HdE https://t.co/1Crjwb…
RT @manabunoda: 今日の夜22時くらいからエビテンをします! 毎度毎度の音声トラブル…今回はうまくいくはず… 今回はこの3つを https://t.co/ZuHnKsXUKt https://t.co/Bibn4X4HdE https://t.co/1Crjwb…
RT @manabunoda: 今日の夜22時くらいからエビテンをします! 毎度毎度の音声トラブル…今回はうまくいくはず… 今回はこの3つを https://t.co/ZuHnKsXUKt https://t.co/Bibn4X4HdE https://t.co/1Crjwb…
RT @manabunoda: 今日の夜22時くらいからエビテンをします! 毎度毎度の音声トラブル…今回はうまくいくはず… 今回はこの3つを https://t.co/ZuHnKsXUKt https://t.co/Bibn4X4HdE https://t.co/1Crjwb…
今日の夜22時くらいからエビテンをします! 毎度毎度の音声トラブル…今回はうまくいくはず… 今回はこの3つを https://t.co/ZuHnKsXUKt https://t.co/Bibn4X4HdE https://t.co/1Crjwbq1Ua https://t.co/HWMjKnkYnG
RT @HengartnerMP: Stressing marginally small and transient benefits at 9-week followup. „At week 25, the treatment arms did not differ in a…
RT @Toshi_FRKW: Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmat…
RT @Toshi_FRKW: Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmat…
RT @HengartnerMP: Stressing marginally small and transient benefits at 9-week followup. „At week 25, the treatment arms did not differ in a…
RT @Toshi_FRKW: Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmat…
Stressing marginally small and transient benefits at 9-week followup. „At week 25, the treatment arms did not differ in any of the efficacy (PHQ-9, BDI-II, remission), acceptability (time to discontinuation of the allocated treatment or of any treatment) o
We found significant benefit in adding or switching to mirtazapine among 1646 patients not remitting on sertraline (differences in BDI-II scores of 2.0 to 1.5, p=0.001). https://t.co/Yd6fAX4F6X
Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial https://t.co/Yd6fAX4F6X
うわ、ついったで論文まわってくるとは・・・。
#Featured article! Optimising first- and second-line #treatments for untreated major #depression https://t.co/7mwpm1F6l7 https://t.co/y2F2SiIaGH
RT @Toshi_FRKW: SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the firs…
RT @And_Cipriani: “In patients with new onset depression, we found no advantage of titrating sertraline to 100 mg vs 50 mg. Patients unremi…
RT @And_Cipriani: “In patients with new onset depression, we found no advantage of titrating sertraline to 100 mg vs 50 mg. Patients unremi…
RT @Toshi_FRKW: SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the firs…
Mirtazapine between 7.5 mg and 45 mg. Mirtazapine between 7.5 mg to 30 mg is a different drug to 45-60 mg. Didn’t really understand the point of trial if they are using sub therapeutic doses for both. https://t.co/lfY0vW1waF
“In patients with new onset depression, we found no advantage of titrating sertraline to 100 mg vs 50 mg. Patients unremitted by wk 3 gained a small benefit at wk 9 by switching sertraline to mirtazapine or by adding mirtazapine” by @Toshi_FRKW https:/
RT @Toshi_FRKW: SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the firs…
Yes, it does. I hope you like it :) https://t.co/eRZ0Uhpkuc https://t.co/vLrv8fdEVm
RT @HengartnerMP: 1/n some notes on this new #antidepressant paper. It shows that titration to the highest dose has no advantage over low d…
RT @Toshi_FRKW: SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the firs…
RT @HengartnerMP: 1/n some notes on this new #antidepressant paper. It shows that titration to the highest dose has no advantage over low d…
RT @Toshi_FRKW: SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the firs…
RT @HengartnerMP: 1/n some notes on this new #antidepressant paper. It shows that titration to the highest dose has no advantage over low d…
RT @Toshi_FRKW: SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the firs…
RT @Toshi_FRKW: SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the firs…
1/n some notes on this new #antidepressant paper. It shows that titration to the highest dose has no advantage over low dose. Why even pursue such an idea? placebo-controlled trials have long established that dose increase has no benefit https://t.co/dQ3gJ
SUN(^_^)D - Strategic Use of New generation antidepressants for Depression: Our pragmatic trial (n=2011) examining the first- and second-line antidepressant treatment strategies for hitherto untreated major depressive episodes has just been published. http
Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. https://t.co/LS8Fk51xH6
RT @BMCMedicine: Optimising first- and second-line #treatment strategies for untreated major #depressive #disorder — the SUN☺D study: a pra…
Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial https://t.co/XDgvzzxq3x
RT @BMCMedicine: Optimising first- and second-line #treatment strategies for untreated major #depressive #disorder — the SUN☺D study: a pra…
Optimising first- and second-line #treatment strategies for untreated major #depressive #disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled #trial https://t.co/7mwpm1F6l7